Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1 , Pages 52-60 , January 2010

Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders

  • Stephen R. Hooper, Ph.D.

      Affiliations

    • University of North Carolina
    • Corresponding Author InformationCorrespondence to Dr. Stephen R. Hooper, Center for Development and Learning, CB# 7255, The Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7255
    • ,
  • Anthony J. Giuliano, Ph.D.

      Affiliations

    • Cambridge Health Alliance, Harvard Medical School
    • ,
  • Eric A. Youngstrom, Ph.D.

      Affiliations

    • University of North Carolina
    • ,
  • David Breiger, Ph.D.

      Affiliations

    • University of Washington
    • ,
  • Linmarie Sikich, M.D.

      Affiliations

    • University of North Carolina
    • ,
  • Jean A. Frazier, M.D.

      Affiliations

    • Cambridge Health Alliance, Harvard Medical School
    • ,
  • Robert L. Findling, M.D.

      Affiliations

    • Case Western Reserve University
    • ,
  • Jon McClellan, M.D.

      Affiliations

    • University of Washington
    • ,
  • Robert M. Hamer, Ph.D.

      Affiliations

    • University of North Carolina
    • ,
  • Benedetto Vitiello, M.D.

      Affiliations

    • National Institutes of Mental Health
    • ,
  • Jeffrey A. Lieberman, M.D.

      Affiliations

    • Columbia University and New York State Psychiatric Institute

,Accepted 21 September 2009.

References 

  1. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol. 1999;11:487–508
  2. Iacono WG, Clementz BA. A strategy for elucidating genetic influence on complex psychopathological syndromes. Prog Exp Psychopath Res. 1993;16:11–65
  3. Kumra S, Wiggs E, Bedwell J, et al. Neuropsychological deficits in pediatric patients with childhood-onset schizophrenia and psychotic disorder not otherwise specified. Schizophr Res. 2000;7:135–144
  4. McClelland J, Prezbindowski A, Breiger D, McCurry C. Neuropsychological functioning in early-onset psychotic disorders. Schizophr Res. 2004;28:21–29
  5. Rhinewine JP, Lencz T, Thaden EP, et al. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry. 2005;58:705–712
  6. Ueland T, Oie N, Landro I, Rund B. Cognitive functioning in adolescents with schizophrenia spectrum disorders. Psychiatry Res. 2004;126:229–239
  7. Walker EF, Savoie T, Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull. 1994;20:453–480
  8. Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. Schizoaffective disorder: a form of schizophrenia or affective disorder. J Clin Psychiatry. 1999;60:874–882
  9. Lake CR, Hurwitz N. Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders. Psychiatry Res. 2006;143:255–287
  10. Malhi GS, Green M, Fagiolini A, Peselow ED, Kumari V. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord. 2008;10:215–230
  11. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime?. Trends Genet. 2006;22:306–310
  12. Kempf L, Hussain N, Potash JB. Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders. Int Rev Psychiatry. 2005;17:9–19
  13. Harrow M, Grossman LS, Herbener ES, Davies EW. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421–426
  14. Jager M, Bottlender R, Strauss A, Moller J. Fifteen-year follow-up of ICD-schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand. 2004;109:117–121
  15. Reinares M, Vieta E, Benabarre A, Marneros A. Clinical course of schizoaffective disorders. In:  Marneros A,  Akiskal AH editor. The Overlap of Affective and Schizophrenic Spectra. Cambridge, UK: Cambridge University Press; 2007;p. 145–155
  16. Beatty WW, Jocic Z, Monson N, Staton RD. Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1993;181:448–453
  17. Verdoux H, Liraud F. Neuropsychological function in subjects with psychotic and affective disorders: relationship to diagnostic category and duration of illness. Eur Psychiatry. 2000;15:236–243
  18. Addington J, Brooks BL, Addington D. Cognitive functioning in first episode psychosis: initial presentation. Schizophr Res. 2003;62:59–64
  19. Fiszdon JM, Richardson R, Greig T, Bell MD. A comparison of basic and social cognition between schizophrenia and schizoaffective disorder. Schizophr Res. 2007;91:117–121
  20. Thaden E, Rhinewine JP, Lencz T. Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the Identical Pairs Continuous Performance Test. Schizophr Res. 2006;81:157–166
  21. Frazier JA, McClellan J, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007;46:979–988
  22. American Psychiatric Association. Diagnostic and Statistical Manual–IV-TR. Washington, DC: American Psychiatric Association; 1994;
  23. Hein D, Matzner F, First M, Spitzer R, Williams J, Gibbons M. Structured clinical interview for DSM-IV childhood disorders, KID-SCID. New York, NY: Department of Psychiatry, Columbia University Medical School; 1998;
  24. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS) (Rationale, design, and methods). J Am Acad Child Adolesc Psychiatry. 2007;46:969–978
  25. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Interpretation. Tucson, AZ: Neuropsychology Press; 1985;
  26. Lafayette Instrument Company. Grooved Pegboard Instruction Manual, Model 32025. Lafayette, IN: Lafayette Instrument Company; 1989;
  27. Cegalis J, Bowlin J. Vigil: Software for the Assessment of Attention. Nashua, NH: Forthought; 1991;
  28. Brandt J. The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–142
  29. Adams W, Sheslow D. The Wide Range Assessment of Memory and Learning. Wilmington, DE: Jastak Associates; 1990;
  30. Hershey T, Selke G, Fucetola R, Newcomer JW. Spatial long-term memory but not working memory decreases over time in schizophrenia [Abstract]. Soc Neuroscience Abs. 1999;25:572
  31. Woodcock RW, McGrew KS, Mather N. Woodcock-Johnson-III Tests of Cognitive Abilities. Chicago, IL: Riverside Publishing; 2001;
  32. Benton AL, Hamscher K. Multilingual Aphasia Examination Manual (revised). Iowa City, IA: University of Iowa; 1978;
  33. Ruff RM, Light RH, Evans RW. The Ruff Figural Fluency Test: a normative study with adults. Dev Neuropsychol. 1987;3:37–51
  34. Heaton RK, Chelune GJ, Taley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993;
  35. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The 'Reading the Mind in the Eyes' test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001;42:241–252
  36. Stano JF. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Psychological Corporation; 1999;
  37. Wilkenson GS. Wide Range Achievement Test–Third Revision. Wilmington, DE: Jastak Associates; 1993;
  38. Keefe RSE, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull. 2003;29:45–55
  39. Kay S, Opler L, Lindenmayer J. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry. 1989;155:59–67
  40. Guy W. Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health; 1976;p. 217–221
  41. Overall J, Pfefferbaum B. The Brief Psychiatric Rating Scale for Children. Psychopharmacol Bull. 1982;18:10–16
  42. Achenbach TM, Rescorla LA. Manual for ASEBA School-Age Forms & Profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001;
  43. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales, Survey Edition. Circle Pines, MN: American Guidance Service; 1984;
  44. Hill SK, Sweeney JA, Hamer RM, et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc. 2008;14:209–221
  45. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549–559
  46. Goldstein G, Shemansky WJ, Allen DN. Cognitive function in schizoaffective disorder and clinical subtypes of schizophrenia. Arch Clin Neuropsychol. 2005;20:153–159
  47. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry. 2008;165:579–587
  48. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multi-method matrix. Psych Bull. 1959;56:81–105
  49. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996;153:321–330
  50. Semkovska M, Bedard M-A, Godbout L, Limoge F, Stip E. Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res. 2004;69:289–300
  51. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull. 2008;34:1111–1121
  52. Addington J. Negative symptoms and the relationship to cognitive functioning. In:  Sharma T,  Harvey P editor. Cognition in Schizophrenia. Oxford, UK: Oxford University Press; 2000;p. 191–209
  53. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1–9
  54. Velligan DI, Mahurin RK, Diamond PL, Hazelton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25:21–31
  55. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539–543
  56. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 2008;40:880–885
  57. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455:232–236
  58. Burdick KE, Goldberg JF, Harrow M, Faull RN, Malhorta AK. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis. 2006;194:255–260

 The Treatment of Early Onset Schizophrenia Spectrum (TEOSS) project was conducted with grant support from the National Institute of Mental Health under cooperative agreements U01MH61528 to the University of North Carolina (P.I.: Lin Sikich), U01MH61464 to the University of Washington (P.I.: Jon McClellan), U01MH62726 to Harvard Medical School (P.I.: Jean Frazier), and U01MH61355 to Case Western Reserve University (P.I.: Robert Findling), and by the Maternal Child Health Bureau (#MCJ379154A), and the Administration on Developmental Disabilities (#90DD043003). The research was conducted in NIH supported Clinical Research Centers at Seattle Children's Hospital, University of Washington (M01-RR-00037) and the University of North Carolina (M01-RR00046).

 The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health.

 Disclosure: Dr. Hooper receives or has received research support or served as a speaker/consultant for Eli Lilly and Sanofi-Aventis. Dr. Youngstrom has previously served on the Data Safety and Monitoring Board for Eli Lilly and consulted in the past with Otsuka. Dr. Sikich has a current financial interest and receives research funding or participates in clinical trials with Janssen, Pfizer, Bristol Myers-Squibb, Neuropharm, Curemark, and Seaside Pharmaceuticals. She also received software for a computer intervention in schizophrenia from Posit Science. In the past, Dr. Sikich received research funding from Eli Lilly, Janssen, Pfizer, Otsuka, and Astra Zeneca, and has served as a consultant for Sanofi Aventis and ABT Associates. Dr. Frazier receives or has received research support and acted as a consultant for Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Findling receives or has received research support, acted as a consultant, and/or served on a speaker's bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, KemPharm, Eli Lilly, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth. Dr. McClellan has had past research support from Pfizer. Dr. Hamer has served as a consultant or advisor for Acadia, Cenerx, Corcept, Epix, Johnson & Johnson, NeuroPharmaBoost, Pepper-Hamilton, PureTechVentures, Sanofi-Aventis, and Takeda. He has served on the advisory board for Enabled MD, Novartis, and Wyeth. He has served on a Data Safety Monitoring Board (DSMB) for Allergan, Eli Lilly & Company, Pfizer, Schwartz, and Solvey. He has served on a Mock Advisory Panel for Alpharma. He has served as a statistician on a University of North Carolina contract for a clinical trial with AstraZeneca. He has taught several seminars for SAS Institute. He has served as an expert witness for Winston-Strawn. He or his wife own stock in Bristol-Myers Squibb, Amgen, Eli Lilly & Company, Genentech, Proctor & Gamble, and Sepracor. Dr. Lieberman serves as a consultant and/or advisor for Astra Zeneca, Bioline, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Pfizer, and Wyeth; and as a member of the Data Safety Monitoring Board (DSMB) for Solvay. He does not receive financial compensation or salary support for this participation as a consultant or as a member of a board. He receives grant support from AstraZeneca, Allon, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Merck, Pfizer, and Wyeth; and he holds a patent from Repligen. Drs. Guiliano, Breiger, and Vitiello report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(09)00013-6

doi: 10.1016/j.jaac.2009.11.001

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1 , Pages 52-60 , January 2010

Article Tools